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Background: To retrospectively assess feasibility and toxicity of proton therapy in patients with low-grade glioma
(WHO °I/II).
Patients and methods: Proton beam therapy only administered in 19 patients (median age 29 years; 9 female,
10 male) for low-grade glioma between 2010 and 2011 was reviewed. In 6 cases proton therapy was performed
due to tumor progression after biopsy, in 8 cases each due to tumor progression after (partial-) resection, and in
5 cases due to tumor progression after chemotherapy. Median total dose applied was 54 GyE (range, 48,6-54 GyE)
in single fractions of median 1.8 GyE. Median clinical target volume was 99 cc (range, 6–463 cc) and treated using
median 2 beams (range, 1–2).
Results: Proton therapy was finished as planned in all cases. At end of proton therapy, 13 patients showed focal
alopecia, 6 patients reported mild fatigue, one patient with temporal tumor localization concentration deficits and
speech errors and one more patient deficits in short-term memory. Four patients did not report any side effects.
During follow-up, one patient presented with pseudo-progression showing worsening of general condition and
brain edema 1–2 months after last irradiation and restitution after 6 months. In the present MR imaging (median
follow-up 5 months; range 0–22 months) 12 patients had stable disease, 2 (1) patients partial (complete) remission,
one more patient pseudo-progression (differential diagnosis: tumor progression) 4 weeks after irradiation
without having had further follow-up imaging so far, and one patient tumor progression approximately 9 months
after irradiation.
Conclusion: Regarding early side effects, mild alopecia was the predominant finding. The rate of alopecia seems to
be due to large treatment volumes as well as the anatomical locations of the target volumes and might be avoided
by using multiple beams and the gantry in the future. Further evaluations including neuropsychological testing are
in preparation.
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In Europe, the estimated annual incidence rate is 4.8 per
100,000 for astrocytic and 0.4 per 100,000 for oligo-
dendroglial central nervous system tumors [1]. Clinical
outcome correlates well with the World Health
Organization (WHO) classification for brain tumors [2]:
with respect to glioma, low-grade glioma (LGG; WHO
Grad II) demonstrate a beneficial prognosis compared to
WHO Grad III and IV tumors. Therefore, not only local* Correspondence: henrik.hauswald@med.uni-heidelberg.de
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reproduction in any medium, provided the orcontrol and survival are important, but also preservation
of quality of life (QOL) as well as neurocognitive func-
tioning. Novel radiation modalities, such as proton beam
treatments, offer a distinct physical profile enabling a
significant reduction of integral dose in the patient. This
leads to sparing of normal brain tissue, potentially redu-
cing the risk of neurocognitive sequelae after radiother-
apy. Since available clinical data is still limited, this
analysis was focused on patients treated with a full course
of proton beam therapy only for LGG at the Heidelberg
Ion Therapy Center to evaluate treatment feasibility and
toxicity.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Overview on patients' characteristics and treatment



















1 male 10 pilocytic astrocytoma WHO °I central no 11 2 10 resection 54 2 45
2 male 38 pilocytic astrocytoma WHO °I central no 35 2 30 resection 54 1,8 20
3 female 12 pilomyxoid astrocytoma WHO °II central yes 48 2 30 chemotherapy 54 1,8 >116
4 male 37 pilocytic astrocytoma WHO °I central no 220 2 30 resection 54 2 44
5 female 17 pilocytic astrocytoma WHO °I central to peripheral no 99 2 70 resection 54 1,8 80
6 male 39 astrocytoma WHO °II central to peripheral no 266 2 70 chemotherapy 54 1,8 69
7 female 12 fibrillary astrocytoma WHO °II central to peripheral no 212 2 90 resection 48,6 1,8 48
8 female 48 astrocytoma WHO °II central to peripheral no 75 1 70 biopsy only 54 2 3
9 female 36 fibrillary astrocytoma WHO °II central to peripheral no 212 2 70 resection 54 1,8 85
10 female 38 astrocytoma WHO °II peripheral no 187 2 70 biopsy only 54 1,8 11
11 female 28 astrocytoma WHO °II central to peripheral no 371 2 70 resection 54 1,8 26
12 male 56 astrocytoma WHO °II central to peripheral no 463 1 70 biopsy only 50,4 1,8 15
13 female 36 oligoastrozytoma WHO °II central to peripheral no 298 2 70 chemotherapy 54 1,8 42
14 male 13 pilocytic astrocytoma WHO °I central yes 204 2 30 chemotherapy 54 1,8 132
15 male 16 pilocytic astrocytoma WHO °I central no 17 2 30 biopsy only 54 1,8 99
16 male 29 pilocytic astrocytoma WHO °I central no 15 2 10 biopsy only 54 2 4
17 male 4 pilocytic astrocytoma WHO °I central no 6 2 30 resection 54 1,8 8
18 male 7 pilocytic astrocytoma WHO °I central yes 19 2 10 chemotherapy 50,4 1,8 33
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Patient characteristics
Between 2010 and 2011, 19 patients (median age 29 years;
range 4–56 years; 9 female, 10 male; 8 patients <18 years)
with LGG (WHO °I/II) were treated with proton therapy
at the Heidelberg Ion Therapy Center at the University
Hospital of Heidelberg. Three patients suffered from op-
tical pathway glioma. One of the pediatric patients was
participating in the HIT-LGG trial, two in the SIOP-LGG
trial and one further pediatric patient had previous ther-
apy based on the SIOP-LGG trial. Proton therapy was
initiated due to tumor progression after initial surgical re-
section in 8 patients, biopsy in 6 patients and chemother-
apy with mainly temozolomide in 5 patients. The median
time interval between initial diagnosis and proton beam
therapy was 38 months (range 3–132 months). Patients’
characteristics are found in Table 1.Figure 1 MR-imaging (T2 Flair sequence, not contrast-
enhanced).Treatment planning
The treatment planning was CT- and MRI-based in all
cases; eventually additional aminoacid-based positron
emission tomography was co-registered for target vol-
ume delineation or definition of high-risk regions. Ad-
equate positioning was achieved by individual head
masks. The target volume concept included delineation
of the gross tumor volume (GTV; defined as the T2-
hyperintensity as well as PET-positive regions) adding a
1–2 cm safety margins for the clinical target volume
(CTV) to include potential microscopic tumor spread.
The planning target volume (PTV) for proton beam
therapy included a margin of 3 mm. The prescribed dose
was defined as the median dose to the PTV. Further-
more, the PTV was encompassed within the 95-107%
isodose level of the prescribed dose. Treatment planning
system was syngo.via by the Siemens AG, Germany. See
Figures 1 and 2 for a treatment planning example, co-
registered is a T2-FLAIR MR-image.Particle therapy
Proton beam therapy delivered a median total dose of
54 GyE (range 48.6-54 GyE) in single fractions of median
1.8 GyE (range 1.8-2 GyE) 5–6 times a week to the PTV
and was performed using a fixed beam line with non-
coplanar beams in active raster-scanning technique with
energies between 48.12 MeV/u and 221.06 MeV/u at the
Heidelberg Ion Therapy Center. The dose concept for
LGG in our institution is 45–54 GyE in 1.8-2 GyE per
fraction, so the dose range of 48.6-54 GyE was due to in-
dividual factors of the patients like young age or the ana-
tomical localization and tumor volume. Proton beam
therapy only was used and not combined with any kind
of photon or heavy-ion beam technique or chemother-
apy. Patient position was verified prior to each singlefraction with orthogonal in-room x-ray imaging. An
overview on the treatment is found in Table 1.
Follow-up and statistics
The first follow-up examination including a MRI of
the brain as well as consultation was performed 6–8
weeks after proton beam therapy and every 2–3 months
afterwards. Neuropsychological tests or perimetric test
of the visual field were not performed on a regular base.
If applicable orientating visual filed tests were per-
formed. Tumor response was described by the modified
MacDonald/RANO Criteria [3]. All time estimates began
with the initiation of proton therapy. Documented side
effects were classified according to CTC AE Version 4.
Approval of the ethics committee Heidelberg was obtained.
Results
Response to treatment
Proton therapy was finished as initially proposed in all
patients. In the latest MRI examinations which were per-
formed after a median follow-up time of 5 months
(range, 0–22 months), 12 patients had stable disease and
2 (1) patients partial (complete) remission. The follow-
up imaging in one juvenile patient with LGG is seen in
Figures 3 and 4. During the follow-up visits, two patients
were diagnosed with pseudo-progression. One of these
two patients presented with pseudo-progression in MRI
showing worsening of general condition and brain
edema approximately 1–2 months after the last treat-
ment day and restitution after 6 months. The other pa-
tient was diagnosed with most likely pseudo-progression
4 weeks after finishing proton therapy based on the
Figure 2 Treatment plan for proton beam therapy including isodose distribution; the orange structure is the GTV, the red structure
the CTV and the blue structure the PTV.
Figure 3 MR-imaging (T2 Flair sequence, not contrast-enhanced)
before initiation of proton beam therapy in a juvenile patient
with LGG.
Figure 4 MR-imaging (T2 Flair sequence, not contrast-enhanced)
during follow-up after proton beam therapy in a juvenile patient
with LGG.
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the patient did not have further follow-up imaging so far
and tumor progression is a valid differential diagnosis.
Furthermore, one patient had to be diagnosed with
tumor progression approximately 9 months after finish-
ing proton treatment.
Side effects
At the end of proton therapy, in 4 patients no acute side
effects were observed. Thirteen patients showed focal
alopecia CTC °II within the proton beam portal of entry.
Radiation induced dermatitis of moderate or higher de-
gree was not documented. Six patients reported mild fa-
tigue. One patient with a tumor localization in the
temporal lobe reported deficits in concentration and
speech errors (CTC °I-II) and one other patient deficits
in short-term memory (CTC °I-II). The documented
maximal acute side effects were seen in Table 2. How-
ever, no formal testing of neurocognitive functioning
was performed. In two patients with optical pathway gli-
oma, tumor-related pre-existing unilateral amaurosis
was documented. Additionally, one of these two patients
had a contralateral hemianopsia. Treatment related vis-
ual field changes were not documented.
Discussion
This analysis reports on outcome of 19 patients treated
between 2010 and 2011 with proton beam therapy for
LGG at the Heidelberg Ion Therapy Center. Proton
beam therapy was applied to a median total dose of
54 GyE in single fractions of median 1.8GyE 5–6 times a
week. Treatment was tolerated without high-grade side
effects. Acute toxicity of the raster-scanning technique
for these low-grade tumors is low. The patients will be
followed prospectively. Due to the relatively long sur-
vival in patients with LGG, long-term side effects as
impaired neurocognitive function become relevant. This
issue was addressed by Brown et al. in a review on neu-
rocognitive effects of radiotherapy in LGG [4]. The
authors concluded that by modern treatment techniques
as MRI-based target volume delineation and the use of
multiple overlapping conformal beams, the impact on
neurocognitive function could be minimized. So, high
conformal and normal brain tissue sparing radiationTable 2 Maximal acute side effects in patients treated
with proton beam therapy for low-grade glioma
Type of side effect n
Alopecia CTC °II 13
Fatigue CTC °I-II 6
Deficits in concentration CTC °I-II 1
Deficits in speech CTC °I-II 1
Deficits in short term memory CTC °I-II 1techniques provide us the potential to further minimize
the risk of late neurocogintive impairment. A treatment
option with a high potential for normal tissue sparing is
e. g. proton beam therapy. Recently Beltran and his team
reported on 14 pediatric patients with craniopharyngioma
treated with 54 Gy photons. On this base different alter-
native treatment plans –including intensity-modulated
radiotherapy, intensity-modulated proton beam therapy
and double-scatter proton beam therapy- were calculated
[5]. The radiation dose to the whole-brain as well as –
body was significantly decreased by proton beam therapy
compared to intensity-modulated radiotherapy. Best
treatment plans concerning conformal target coverage
and sparing of normal tissue were achieved by intensity-
modulated proton beam therapy while being very vulner-
able to variations of the target volume on the other hand.
Furthermore, not only in children but also adults the risk
for secondary cancers after initial radiotherapy becomes
crucial. A treatment plan comparison by Athar and Paga-
netti showed that scanned proton beam therapy had the
lowest risk for out-of-field secondary cancers during life-
time compared to passive scattered proton therapy or
intensity-modulated radiotherapy [6]. Furthermore, the
risk for developing secondary cancers after irradiation of
the brain was retrospectively analyzed in 370 children
with a median age of 8.1 years by Galloway et al.: In
total, 18 secondary cancers were diagnosed in 16 patients
median 18.9 years after the associated radiation therapy
[7]. The median time to diagnosis of secondary meningi-
oma (n=10) was 22 years, while secondary glioma (n=4)
were diagnosed after median 15 years. The incidence
rates for secondary cancers at 10, 20 and 30 years after
the associated irradiation in childhood were 3%, 8% and
24%, respectively. In conclusion, it seems justified to us,
to perform radiation treatments especially in -but not
only- children and young adults, if possible as a proton
beam therapy, optimally with scanned protons. Clinical
data on particle therapy in LGG is rare. In 2002 the
colleagues from Loma Linda reported on the first
27 pediatric patients treated with proton beam therapy
for LGG [8]. The mean age at time of treatment was
8.7 years and treatment doses between 50.4 GyE and
63.0 GyE in single fractions of 1.8 GyE. The mean
follow-up time was 3.3 years and 6 patents were reported
to have in-field tumor recurrence. All children with local
tumor control maintained their performance status. So
the authors concluded that proton beam therapy is safe
and efficacious, especially in situations, when high dose
conformity is warranted due to central tumors or close
relation to the optic pathway. The colleagues from Chiba
recently published the results on 14 patients treated be-
tween 1994 and 2002 with carbon ions for WHO °II dif-
fuse astrocytoma in a dose-escalation study [9]. The
patients were treated with 50.4 to 55.2 GyE carbon ions
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the treatment dose. Patients in the high-dose group
(55.2 GyE, n=5) showed a significantly longer median
progression-free survival (91 months vs. 18 months) as
well as median overall survival compared to the low-dose
group (46.2-50.4 GyE, n=9). The median overall survival
for all Patients was 53.4 months and the 5- and 10-year
overall survival rates were 43% and 36%, respectively.
Acute side effects were minor, while 2 patients of each
group had MR-imaging based LENT-SOMA grade 3 late
reactions of the brain. These grade 3 late reactions
regressed ether spontaneously or after short course of
steroids.
Considering MRI-based follow-up examinations, the
differentiation of treatment related effects (including ra-
diation necrosis) and tumor progression might be prob-
lematic. The rate of radiation induced brain necrosis in
glioma patients treated with radiotherapy alone is up to
3.4%, while radiation induced brain necrosis seemed to
be unlikely in radiation doses below 50 Gy in 25
fractions but increased with addition of concurrent
chemotherapy [10]. Meyzer et al. reported on a n asymp-
tomatic 14 years old boy presenting with new contrast
enhancement 6 months after proton therapy (54 GyE)
for a low-grade oligodendroglioma located in the tectal
region [11]. The colleagues performed a dynamic sus-
ceptibility contrast MR-imaging as previously described
for differentiation between post-treatment changes and
high-grade glioma recurrence by Hu et al. [12]. Meyzer
et al. favoured the hypothesis of pseudo-progression,
which was treated with weight-adapted oral steroids for
one month. Follow-up MR-imaging showed gradual im-
provement and finally complete resolution of these
changes in MR-imaging. Furthermore, MR-spectroscopy
can help in differentiation between tumor recurrence
and radiogenic changes [13]. However, recently the col-
leagues from the German Cancer Research Center com-
pared dynamic susceptibility-weighted contrast-enhanced
(DSC), dynamic contrast-enhanced (DCE), and proton
spectroscopic imaging ((1)H-MRSI) for treatment moni-
toring and concluded that DSC MR-imaging would be
best for identification of tumor progression in glioma
[14]. Pseudo-progression occurred in our ladder in 11%
of patients. Still, pseudo-progression is a challenging
problem during follow-up examinations and could cause
emotional stress not only in the affected patients. Radio-
biological effects on the skin were reviewed for example
by Malkinson et al. in 1981 and described as injure to
the cutaneous vasculature and germinative cells causing
for example reproductive failure [15]. Radiogenic effects
in the hair matrix cells could cause alopecia, which might
be permanently in dosages of 7–8 Gy or more. The rela-
tively high rate of alopecia within the proton beam portal
of entry in our cohort seems to be related to theanatomical situation and the localization of the target
volumes with isodose levels of up to 90% within the
scalp. In an upcoming study at our institution, the treat-
ment of patients with LGG will be evaluated prospect-
ively including neuropsychological testing to further
improve the knowledge on proton beam therapy in LGG
and its effects on quality of life and neuropsychological
function.
Conclusion
Regarding early side effects, mild alopecia was the pre-
dominant finding. The rate of alopecia seems due to
large treatment volumes as well as the anatomical loca-
tions of the target volumes and might be avoided by
using multiple beams as well as the gantry in the
future. Further evaluations within a prospective clinical
trial, including neuropsychological assessment, are in
preparation.
Competing interests
No competing interests do exist.
Authors’ contributions
HH: analysis and interpretation of data, writing manuscript SR: critically
revision for important intellectual content, interpretation of data SE:
acquisition and analysis of data KK: acquisition and analysis of data KH:
critically revision for important intellectual content, interpretation of data JD:
critically revision for important intellectual content, interpretation of data
SEC: substantial contributions to conception and design; critically revision for
important intellectual content; final approval for publication. All authors have
read and approved the final manuscript.
Received: 14 June 2012 Accepted: 1 November 2012
Published: 9 November 2012
References
1. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC,
Ricardi U, Slowinski J, Brandes A: Epidemiology of glial and non-glial brain
tumours in Europe. Oxford, England: European Journal of Cancer; 1990. 2012.
2. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of
brain tumours. Brain Pathol 1993, 3:255–268.
3. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJB, Jaeckle K, Junck L,
Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert
BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM,
Jacobs AH: Response assessment in neuro-oncology (a report of the
RANO group): assessment of outcome in trials of diffuse low-grade
gliomas. Lancet Oncol 2011, 12:583–593.
4. Brown PD, Buckner JC, Uhm JH, Shaw EG: The neurocognitive effects of
radiation in adult low-grade glioma patients. Neuro Oncol 2003,
5:161–167.
5. Beltran C, Roca M, Merchant TE: On the benefits and risks of proton
therapy in pediatric craniopharyngioma. Int J Radiat Oncol Biol Phys 2012,
82:e281–e287.
6. Athar BS, Paganetti H: Comparison of second cancer risk due to out-of-
field doses from 6-MV IMRT and proton therapy based on 6 pediatric
patient treatment plans. Radiother Oncol 2011, 98:87–92.
7. Galloway TJ, Indelicato DJ, Amdur RJ, Swanson EL, Smith AA, Marcus RB:
Second tumors in pediatric patients treated with radiotherapy to the
central nervous system. Am J Clin Oncol 2011, [Epub ahead of print]
PubMed PMID: 21383606.
8. Hug EB, Muenter MW, Archambeau JO, DeVries A, Liwnicz B, Loredo LN,
Grove RI, Slater JD: Conformal proton radiation therapy for pediatric
low-grade astrocytomas. Strahlenther Onkol 2002, 178:10–17.
9. Hasegawa A, Mizoe J-E, Tsujii H, Kamada T, Jingu K, Iwadate Y, Nakazato Y,
Matsutani M, Takakura K: Experience With Carbon Ion Radiotherapy for
Hauswald et al. Radiation Oncology 2012, 7:189 Page 7 of 7
http://www.ro-journal.com/content/7/1/189WHO Grade 2 Diffuse Astrocytomas. Int J Radiat Oncol Biol Phys 2012,
83:100–106.
10. Ruben JD, Dally M, Bailey M, Smith R, McLean CA, Fedele P: Cerebral
radiation necrosis: incidence, outcomes, and risk factors with emphasis
on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys
2006, 65:499–508.
11. Meyzer C, Dhermain F, Ducreux D, Habrand J-L, Varlet P, Sainte-Rose C,
Dufour C, Grill J: A case report of pseudoprogression followed by
complete remission after proton-beam irradiation for a low-grade
glioma in a teenager: the value of dynamic contrast-enhanced MRI.
Radiat Oncol 2010, 5:9.
12. Hu LS, Baxter LC, Smith KA, Feuerstein BG, Karis JP, Eschbacher JM, Coons
SW, Nakaji P, Yeh RF, Debbins J, Heiserman JE: Relative cerebral blood
volume values to differentiate high-grade glioma recurrence from
posttreatment radiation effect: direct correlation between image-guided
tissue histopathology and localized dynamic susceptibility-weighted
contrast-enhanced perfusion MR imaging measurements. AJNR Am J
Neuroradiol 2009, 30:552–558.
13. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G: Proton
MR spectroscopic evaluation of suspicious brain lesions after stereotactic
radiotherapy. AJNR Am J Neuroradiol 2001, 22:1316–1324.
14. Vöglein J, Tüttenberg J, Weimer M, Gerigk L, Kauczor H-U, Essig M, Weber
M-A: Treatment monitoring in gliomas: comparison of dynamic
susceptibility-weighted contrast-enhanced and spectroscopic MRI
techniques for identifying treatment failure. Invest Radiol 2011,
46:390–400.
15. Malkinson FD, Keane JT: Radiobiology of the skin: review of some effects
on epidermis and hair. J Invest Dermatol 1981, 77:133–138.
doi:10.1186/1748-717X-7-189
Cite this article as: Hauswald et al.: First experiences in treatment of
low-grade glioma grade I and II with proton therapy. Radiation Oncology
2012 7:189.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
